182 related articles for article (PubMed ID: 24774305)
1. Effect of ambrisentan on digital ulcers in systemic sclerosis: a case report.
Tomaselli V; D'Ambrosio D; Massarelli L; Roccatello D
Clin Exp Rheumatol; 2014; 32(6 Suppl 86):S-230-1. PubMed ID: 24774305
[No Abstract] [Full Text] [Related]
2. Efficacy of ambrisentan in the treatment of digital ulcers in patients with systemic sclerosis: a preliminary study.
Parisi S; Peroni CL; Laganà A; Scarati M; Ambrogio F; Bruzzone M; Fusaro E
Rheumatology (Oxford); 2013 Jun; 52(6):1142-4. PubMed ID: 23463806
[No Abstract] [Full Text] [Related]
3. Effect of the endothelin type A-selective endothelin receptor antagonist ambrisentan on digital ulcers in patients with systemic sclerosis: results of a prospective pilot study.
Chung L; Ball K; Yaqub A; Lingala B; Fiorentino D
J Am Acad Dermatol; 2014 Aug; 71(2):400-1. PubMed ID: 25037794
[No Abstract] [Full Text] [Related]
4. Brief report: effect of ambrisentan treatment on exercise-induced pulmonary hypertension in systemic sclerosis: a prospective single-center, open-label pilot study.
Saggar R; Khanna D; Shapiro S; Furst DE; Maranian P; Clements P; Abtin F; Dua S; Belperio J; Saggar R
Arthritis Rheum; 2012 Dec; 64(12):4072-7. PubMed ID: 22777623
[TBL] [Abstract][Full Text] [Related]
5. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial.
Coghlan JG; Galiè N; Barberà JA; Frost AE; Ghofrani HA; Hoeper MM; Kuwana M; McLaughlin VV; Peacock AJ; Simonneau G; Vachiéry JL; Blair C; Gillies H; Miller KL; Harris JHN; Langley J; Rubin LJ;
Ann Rheum Dis; 2017 Jul; 76(7):1219-1227. PubMed ID: 28039187
[TBL] [Abstract][Full Text] [Related]
6. Endothelin receptor antagonists as disease modifiers in systemic sclerosis.
Shetty N; Derk CT
Inflamm Allergy Drug Targets; 2011 Feb; 10(1):19-26. PubMed ID: 21184655
[TBL] [Abstract][Full Text] [Related]
7. Bosentan for digital ulcers in patients with systemic sclerosis: a prospective 3-year followup study.
Tsifetaki N; Botzoris V; Alamanos Y; Argyriou E; Zioga A; Drosos AA
J Rheumatol; 2009 Jul; 36(7):1550-2. PubMed ID: 19567637
[No Abstract] [Full Text] [Related]
8. Bosentan as a rescue therapy in scleroderma refractory digital ulcers.
Chamaillard M; Heliot-Hosten I; Constans J; Taïeb A
Arch Dermatol; 2007 Jan; 143(1):125-6. PubMed ID: 17224564
[No Abstract] [Full Text] [Related]
9. Pulmonary arterial hypertension in connective tissue diseases.
Goldberg A
Cardiol Rev; 2010; 18(2):85-8. PubMed ID: 20160534
[TBL] [Abstract][Full Text] [Related]
10. Screening and Early Detection of Pulmonary Arterial Hypertension in Connective Tissue Diseases. It Is Time to Institute It!
Khanna D; McLaughlin V
Am J Respir Crit Care Med; 2015 Nov; 192(9):1032-3. PubMed ID: 26517415
[No Abstract] [Full Text] [Related]
11. Ambrisentan (Letairis) and tadalafil (Adcirca) for pulmonary arterial hypertension.
Med Lett Drugs Ther; 2016 Jan; 58(1485):2-4. PubMed ID: 26714240
[No Abstract] [Full Text] [Related]
12. Bosentan in systemic sclerosis.
Heresi GA; Minai OA
Drugs Today (Barc); 2008 Jun; 44(6):415-28. PubMed ID: 18596996
[TBL] [Abstract][Full Text] [Related]
13. Challenges in measuring outcomes: size assessment of an individual cutaneous lesion.
Okon L; Werth VP
J Am Acad Dermatol; 2014 Aug; 71(2):402-4. PubMed ID: 25037795
[No Abstract] [Full Text] [Related]
14. Interaction of ambrisentan and phenprocoumon in patients with pulmonary hypertension.
Sommer N; Grimminger J; Ghofrani HA; Tiede H
Pulm Pharmacol Ther; 2014 Jun; 28(1):87-89. PubMed ID: 24650719
[No Abstract] [Full Text] [Related]
15. Resolution of severe digital ulceration during a course of Bosentan therapy.
Snyder MJ; Jacobs MR; Grau RG; Wilkes DS; Knox KS
Ann Intern Med; 2005 May; 142(9):802-3. PubMed ID: 15867420
[No Abstract] [Full Text] [Related]
16. Effect of ambrisentan on peripheral circulation in patients with systemic sclerosis.
Sumida H; Asano Y; Hatano M; Aozasa N; Toyama T; Akamata K; Miyazaki M; Taniguchi T; Takahashi T; Ichimura Y; Noda S; Kuwano Y; Yanaba K; Sato S
Mod Rheumatol; 2016; 26(3):454-7. PubMed ID: 24593173
[TBL] [Abstract][Full Text] [Related]
17. Bosentan for digital ulcers in patients with systemic sclerosis.
Nagai Y; Hasegawa M; Hattori T; Okada E; Tago O; Ishikawa O
J Dermatol; 2012 Jan; 39(1):48-51. PubMed ID: 21955007
[TBL] [Abstract][Full Text] [Related]
18. Ambrisentan and its role in the management of pulmonary arterial hypertension.
Macintyre IM; Dhaun N; Goddard J; Webb DJ
Drugs Today (Barc); 2008 Dec; 44(12):875-85. PubMed ID: 19198697
[TBL] [Abstract][Full Text] [Related]
19. Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension.
Hassoun PM; Zamanian RT; Damico R; Lechtzin N; Khair R; Kolb TM; Tedford RJ; Hulme OL; Housten T; Pisanello C; Sato T; Pullins EH; Corona-Villalobos CP; Zimmerman SL; Gashouta MA; Minai OA; Torres F; Girgis RE; Chin K; Mathai SC
Am J Respir Crit Care Med; 2015 Nov; 192(9):1102-10. PubMed ID: 26360334
[TBL] [Abstract][Full Text] [Related]
20. Bosentan is effective against digital ulcerations and hyperkeratosis in systemic sclerosis.
Kurgyis Z; Varga R; Sick I; Lang MU; Ruzicka T; Sárdy M
Acta Derm Venereol; 2011 Oct; 91(6):716-7. PubMed ID: 21879251
[No Abstract] [Full Text] [Related]
[Next] [New Search]
